Taiwan · Delayed Price · Currency is TWD Syngen Biotech Statistics
Total Valuation
Syngen Biotech has a market cap or net worth of TWD 2.26 billion. The enterprise value is 2.17 billion.
| Market Cap | 2.26B |
| Enterprise Value | 2.17B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | Jun 25, 2026 |
Share Statistics
Syngen Biotech has 27.10 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | 27.10M |
| Shares Outstanding | 27.10M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 7.00% |
| Owned by Institutions (%) | 3.18% |
| Float | 10.96M |
Valuation Ratios
The trailing PE ratio is 11.06.
| PE Ratio | 11.06 |
| Forward PE | n/a |
| PS Ratio | 1.10 |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.95 |
| P/FCF Ratio | 9.44 |
| P/OCF Ratio | 7.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.94, with an EV/FCF ratio of 9.05.
| EV / Earnings | 10.58 |
| EV / Sales | 1.06 |
| EV / EBITDA | 5.94 |
| EV / EBIT | 8.65 |
| EV / FCF | 9.05 |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.12 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.63 |
| Debt / FCF | 0.95 |
| Interest Coverage | 64.71 |
Financial Efficiency
Return on equity (ROE) is 8.64% and return on invested capital (ROIC) is 8.67%.
| Return on Equity (ROE) | 8.64% |
| Return on Assets (ROA) | 5.01% |
| Return on Invested Capital (ROIC) | 8.67% |
| Return on Capital Employed (ROCE) | 9.75% |
| Weighted Average Cost of Capital (WACC) | 4.62% |
| Revenue Per Employee | 8.29M |
| Profits Per Employee | 828,826 |
| Employee Count | 247 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 3.71 |
Taxes
In the past 12 months, Syngen Biotech has paid 50.36 million in taxes.
| Income Tax | 50.36M |
| Effective Tax Rate | 19.74% |
Stock Price Statistics
The stock price has decreased by -39.12% in the last 52 weeks. The beta is 0.13, so Syngen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -39.12% |
| 50-Day Moving Average | 80.61 |
| 200-Day Moving Average | 98.89 |
| Relative Strength Index (RSI) | 60.19 |
| Average Volume (20 Days) | 29,514 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Syngen Biotech had revenue of TWD 2.05 billion and earned 204.72 million in profits. Earnings per share was 7.54.
| Revenue | 2.05B |
| Gross Profit | 635.67M |
| Operating Income | 248.87M |
| Pretax Income | 255.08M |
| Net Income | 204.72M |
| EBITDA | 347.22M |
| EBIT | 248.87M |
| Earnings Per Share (EPS) | 7.54 |
Balance Sheet
The company has 322.49 million in cash and 228.61 million in debt, with a net cash position of 93.88 million or 3.46 per share.
| Cash & Cash Equivalents | 322.49M |
| Total Debt | 228.61M |
| Net Cash | 93.88M |
| Net Cash Per Share | 3.46 |
| Equity (Book Value) | 2.40B |
| Book Value Per Share | 88.71 |
| Working Capital | 657.70M |
Cash Flow
In the last 12 months, operating cash flow was 319.82 million and capital expenditures -80.34 million, giving a free cash flow of 239.48 million.
| Operating Cash Flow | 319.82M |
| Capital Expenditures | -80.34M |
| Depreciation & Amortization | 98.35M |
| Net Borrowing | -64.33M |
| Free Cash Flow | 239.48M |
| FCF Per Share | 8.84 |
Margins
Gross margin is 31.04%, with operating and profit margins of 12.15% and 10.00%.
| Gross Margin | 31.04% |
| Operating Margin | 12.15% |
| Pretax Margin | 12.46% |
| Profit Margin | 10.00% |
| EBITDA Margin | 16.95% |
| EBIT Margin | 12.15% |
| FCF Margin | 11.69% |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 6.00%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 6.00% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 66.19% |
| FCF Payout Ratio | 56.58% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 5.93% |
| Earnings Yield | 9.04% |
| FCF Yield | 10.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.
| Last Split Date | Jul 9, 2018 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Syngen Biotech has an Altman Z-Score of 4.21 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.21 |
| Piotroski F-Score | 5 |